PTC Therapeutics, Inc. (PTCT)
PTCT Stock Price Chart
Explore PTC Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze PTCT price movements and trends.
PTCT Company Profile
Discover essential business fundamentals and corporate details for PTC Therapeutics, Inc. (PTCT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
20 Jun 2013
Employees
939.00
Website
https://www.ptcbio.comCEO
Matthew Klein
Description
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
PTCT Financial Timeline
Browse a chronological timeline of PTC Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $0.28, while revenue estimate is $295.38m.
Earnings released on 7 May 2026
EPS came in at -$0.03 surpassing the estimated -$0.45 by +93.33%, while revenue for the quarter reached $272.55m , beating expectations by +25.36%.
Earnings released on 19 Feb 2026
EPS came in at -$1.67 falling short of the estimated -$0.21 by -695.24%, while revenue for the quarter reached $164.68m , missing expectations by -41.08%.
Earnings released on 4 Nov 2025
EPS came in at $0.20 surpassing the estimated -$1.19 by +116.81%, while revenue for the quarter reached $211.01m , missing expectations by -25.03%.
Earnings released on 7 Aug 2025
EPS came in at -$0.83 surpassing the estimated -$1.07 by +22.43%, while revenue for the quarter reached $178.88m , missing expectations by -6.57%.
Earnings released on 6 May 2025
EPS came in at $10.04 surpassing the estimated -$1.08 by +1.03k%, while revenue for the quarter reached $1.18bn , beating expectations by +215.64%.
Earnings released on 27 Feb 2025
EPS came in at -$0.24 surpassing the estimated -$1.12 by +78.57%, while revenue for the quarter reached $213.17m , missing expectations by -14.39%.
Earnings released on 7 Nov 2024
EPS came in at -$1.39 surpassing the estimated -$1.54 by +9.74%, while revenue for the quarter reached $196.79m , beating expectations by +3.31%.
Earnings released on 8 Aug 2024
EPS came in at -$1.16 falling short of the estimated -$1.00 by -16.00%, while revenue for the quarter reached $186.70m , beating expectations by +0.75%.
Earnings released on 25 Apr 2024
EPS came in at -$1.20 surpassing the estimated -$1.21 by +0.83%, while revenue for the quarter reached $210.12m , beating expectations by +23.29%.
Earnings released on 29 Feb 2024
EPS came in at -$0.24 falling short of the estimated $0.29 by -182.76%, while revenue for the quarter reached $307.06m , missing expectations by -4.43%.
Earnings released on 26 Oct 2023
EPS came in at -$1.76 falling short of the estimated -$0.85 by -107.06%, while revenue for the quarter reached $196.58m , missing expectations by -6.48%.
Earnings released on 3 Aug 2023
EPS came in at -$2.66 falling short of the estimated -$1.58 by -68.35%, while revenue for the quarter reached $213.81m , beating expectations by +3.29%.
Earnings released on 27 Apr 2023
EPS came in at -$1.88 falling short of the estimated -$1.64 by -14.63%, while revenue for the quarter reached $220.38m , beating expectations by +7.78%.
Earnings released on 21 Feb 2023
EPS came in at -$2.35 falling short of the estimated -$1.96 by -19.90%, while revenue for the quarter reached $167.41m , missing expectations by -11.13%.
Earnings released on 27 Oct 2022
EPS came in at -$1.53 falling short of the estimated -$1.37 by -11.68%, while revenue for the quarter reached $217.13m , beating expectations by +21.63%.
Earnings released on 4 Aug 2022
EPS came in at -$2.13 falling short of the estimated -$1.67 by -27.54%, while revenue for the quarter reached $165.53m , beating expectations by +2.10%.
Earnings released on 3 May 2022
EPS came in at -$1.78 falling short of the estimated -$1.55 by -14.84%, while revenue for the quarter reached $148.74m , beating expectations by +1.24%.
Earnings released on 22 Feb 2022
EPS came in at -$2.03 falling short of the estimated -$1.79 by -13.41%, while revenue for the quarter reached $165.23m , beating expectations by +9.55%.
Earnings released on 28 Oct 2021
EPS came in at -$1.89 falling short of the estimated -$1.78 by -6.18%, while revenue for the quarter reached $138.74m , beating expectations by +9.73%.
Earnings released on 29 Jul 2021
EPS came in at -$1.68 surpassing the estimated -$1.84 by +8.70%, while revenue for the quarter reached $116.68m , meeting expectations.
PTCT Stock Performance
Access detailed PTCT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
